Source: International Congress 2019 – Novel findings from asthma clinical trials
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Simpson (Newcastle, Australia), D. Barker (Newcastle, Australia), I. Yang (Brisbane, Australia), J. Upham (Brisbane, Australia), P. Reynolds (Adelaide, Australia), S. Hodge (Adelaide, Australia), A. James (Perth, Australia), C. Jenkins (Sydney, Australia), M. Peters (Sydney, Australia), G. Marks (Sydney, Australia), M. Baraket (Sydney, Australia), P. Gibson (Newcastle, Australia). Azithromycin add-on therapy reduces airway inflammation and extracellular DNA: An AMAZES sub-study.. 5338

Member's Comments

No comment yet.

Related content which might interest you: Montelukast as add-on therapy may improve some indices of small airways involvement in uncontrolled asthmatics Source: Annual Congress 2011 - Asthma management and response Year: 2011 Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design Source: ERJ Open Res, 6 (2) 00333-2019; 10.1183/23120541.00333-2019 Year: 2020 Sputum IL-1ß is reduced with Azithromycin add-on therapy in patients with poorly controlled asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Severe therapy resistant asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=312 Year: 2003 Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Increased sputum FKBP51 gene expression following Azithromycin add-on therapy in asthma Source: International Congress 2018 – New modalities in asthma treatment Year: 2018 Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Inhaled budesonide suppresses airway and systemic eosinophilic inflammation in COPD. No predictive value of a prednisolone test treatment Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005 Long-term macrolide therapy in chronic inflammatory airway diseases Source: Eur Respir J 2009; 33: 171-181 Year: 2009 The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003 Proof of concept study to evaluate step down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007 Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Effect of bosentan on MMP-7 levels as add-on therapy in idiopathic pulmonary fibrosis. A prospective study Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy Source: Eur Respir J 2013; 42: 350-361 Year: 2013 Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy Source: Eur Respir J 2014; 43: 1208-1211 Year: 2014 Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy Source: Eur Respir J 2014; 43: 1211-1212 Year: 2014